Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Was a shame there was no video recording of the ASM. The scenes of the man in red could have gone viral.
Did anybody figure out if he was the new BOD member? He looked really, really excited.
EDIT: Did the "oh, the mike is live" audio get captured in the audio recording, or did they edit that out?
Every inventor assigns their rights separately. All versions of the combo patent are presently assigned to all 4 of NWBO, Revimune, CRL and NIH.
What that means is all 4 can use the invention (which s the idea of treating a GBM patient with both an ATL-DC and a CI). And all 4 can license it,
The NIH does not matter. It is standard for University work done under a NIH grant to be assigned back to them, but they rarely (if ever) use it.
It is unclear if the -L application would qualify for the "high quality application" standard that yields the 150 day review.
Yes, we know they took a lot of time to triple check the submission. We know they switched to a new set of consultants late in the game to insure it was done. And we know from Senti and others that LP and LG personally took over the final submission because the consultants were not getting it done.. But still, one might wonder.
That it took till March to get validation verified might make one suspect the quality was not as high as all the longs here assume.
And if so, then the deadline would move to 210+60. And after that one can blame MHRA for being slow.
On an ironic side note, I wonder when KIPK will learn that I get paid based on total emojoes regardless of positive/negative?
We know a lot of details wrt Advent.
There are 3 operational contracts (outside the leas).
1) The mfg agreement to run Specials in Sawston. $8.3M/year. This includes a minimum manufacturing quantity and presumably operational costs for the program.
2) The mfg agreement to run Specials out of London. $6.6M/year. Same as above
3) The Ancillary Services agreement that is an umbrella contract under which Advent provides various work at cost + 15% (?).
On the first 2 they are paying about twice what the paid Cognate because of the 2 facilities. We know after LP sold off Cognate she stopped paying Cognate and claimed it was an unfair contract, But now she pays Advent twice as much. and why 2 facilities? Certainly not at capacity now, and is not Sawston much bigger?
For the services, there are certainly many recent SOWs that are as you say and I cannot question. But there were also the contracts to build out Sawston. The clean rooms, the freezers etc. Advent was paid cost plus to have those installed, and now they are Advent's by way of the $140K/year lease on the GMP (phase 1A and 1B) portion of facility. That is insane.
And last, we have the comical costs where NWBO paid Advent to transfer the tech from Cognate when they had already Paid Cognate to set it up. By that logic Advent could restructure every year to get more cash for "transferring" the tech
At the end f the day we do know Advent has managed to set up a profit making CDMO on virtually no cash. They have an approved facility under long term lease for chump change. .
You are still posting NWBO's counter to the MTD. There are no quotes in that from MMs. The actual material from the MTD was:
The quoted text is what the FAC (First Ammended Complaint) alleges. So that is NWBO quoting themselves.
Except they did not admit to spoofing. Just more message board nonsense.
Making statements along the lines of "even if we traded the orders for our own accounts then ..." is not an admission they did. It is just a hypothetical arguing a further point. Further, even if they had admitted they placed the orders, that in itself is not spoofing.
The MTD (both versions) are public documents. Feel free to actually show any admission of guilt. You can't.
She said "basically the same".
One can say Keytruda and Opdivo are basically the same. Once can say Coke and Pepsi are basically the same. Once can say a Ford Escape and Mazda Tribute are basically the same,.
I will take the documented evidence in the JAMA paper that asserts they use distinct manufacturing processes.
Show me any RA that has approved it (Hiltonol). You can't. It is not approved by any RA. They are easy to find.
Nobody can be so stupid as to think it is approved when even Oncovir says it is not approved.
And your argument on ATL-DC being DCVax-L is also wrong.Yes, UCLA has has agreements with NWBO. And yes, their ATL-DC is basically the same as -L. That does not make them the same. We know the manufacturing process is different, and NWBO has made great pains to not how there process is special and secret.
Then show me the actual FDA/EMA (or any RA) approval.
It is not that friggen complicated. Every approved drug is listed by actual RAs as being approved. Finding one random site that incorrectly states it is approved does not make it so.
Even Oncovir says the drug is not approved.
Not surprising you are long NWBO.
Anybody asserting Hiltonol is approved so therefor can be prescribed off label is just posting BS crap.
Anybody can look up every approved FDA/EMA drug very easy. Will mot find it listed on either website. Will not find any "Hiltonol prescribing label" as you can easily find for any approved drug Amazes me how many will keep accepting his lies when they can be validated in under a minute.
Tool on.
I would rather the clock was known to start back in Jan, that way when Fall turns to Winter longs will be a bit more worried about the lack of news.
But up to everybody to interpret what exactly LP said with the 2 dates. I suspect she is saying they passed the first phase of validation and were informed of that in Jan, but the second phase was not validated until March.
Not they they would not blatantly lie if they feel like it. Either LG or LP had to lie about number of specials patients. Also, they have failed to disclose negative material news in a timely manner in the past, so the assertion by LG that they would have had to now is a lie. They also have made plenty of technically forward looking statements that were clearly BS.
The MTD decision will almost certainly be before any MHRA news. I think a MTD rejection is most likely, but not a certainty.
I seriously doubt it has any significant impact on the price. But whatever, at least t s something that will actually happen.
The idea that it is BP is out of fantasy land. To BP, NWBO is just one more startup bio that has not shown enough to warrant buying or partnering.
If there is spoofing, and the culprit is found, the obvious candidates are the "investors" buying shares from NWBO. Those are the ones who have a direct profit motive.
Anybody notice how the prices dropped into the close the entire two weeks before the SIO deal closed? Anybody noted the 10's millions shares sold by NWBO around 5/10/22? Anybody remember the same pattern over and over where an uptick in the PPS was countered by an unexplained drop only to find NWBO was selling discount shares?
The Island Boys are scum that scavenge off of caucuses of near dead (financially) companies.
I doubt the actual number really jumped. Looks like for some reason they went from reporting owners of record to beneficial owners.
Owners of record is fairly small as for most all it is in street name.
So GENOCEA BIOSCIENCES contracted Oncovir 6 years ago to have them supply Poly-ICLC for whatever they were developing. Big deal. As it notes, it is clinical, not commercial.
Sure, if Genocea's product would be (or even is) approved, then the API they used in it (including PolyICLC) would need to be approved as a material to be used in commercial applications.
If you want to know if Hiltonol is FDA approved, try the FDA website. It says no.